Streetbeat News

Analyst Ratings

IREN

Iris Energy (NASDAQ:IREN) has received mixed analyst ratings, with a majority being bullish. Analysts have set a 12-month average price target of $16.53, reflecting a slight increase from previous targets. The company's financial performance shows strong revenue growth and effective asset utilization, despite a negative net margin and ROE. Analysts have adjusted their ratings and price targets based on recent developments.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 4:01 pm

U

Unity Software (NYSE:U) has received mixed analyst ratings, with a recent decrease in average price target by 17.29%. Analysts have provided a range of price targets from $10.00 to $33.50. The company faces challenges with declining revenue, low net margins, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 4:01 pm

PK

Park Hotels & Resorts (NYSE:PK) has received mixed analyst ratings over the past three months, with a recent decrease in average price target by 12.64%. Analysts have lowered their price targets, reflecting a negative sentiment shift. Despite challenges in revenue growth, the company shows strong financial health with high net margin, ROE, and ROA, and a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 4:01 pm

ALGN

Align Tech (NASDAQ:ALGN) has been analyzed by 7 analysts, showing a range of perspectives from bullish to bearish. The average 12-month price target is $325, down 7.07% from the previous $349.71. Analysts have adjusted their ratings and price targets, reflecting evolving market conditions. Align Tech is a leading manufacturer of clear aligners, with strong financial metrics such as a high net margin and ROE, but its revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 4:00 pm

NBIX

Neurocrine Biosciences' phase two trial of luvadaxistat for schizophrenia failed to meet its primary endpoint, leading the company to halt its development. Instead, Neurocrine will focus on advancing NBI-1117568 for schizophrenia and NBI-1065845 for major depressive disorder. Despite the setback, analysts maintain an Outperform rating on the stock, citing potential in other areas.

Portfolio Pulse from Vandana Singh

September 13, 2024 | 4:00 pm

CNO

CNO Financial Group (NYSE:CNO) has been analyzed by five analysts, showing a range of ratings from somewhat bullish to somewhat bearish. The average 12-month price target has increased to $33.2, reflecting an 8.5% rise. Analysts have adjusted their ratings and price targets, with some maintaining or raising their outlook. CNO's financial performance shows a 4.24% revenue growth, a strong net margin of 10.91%, and a high ROE of 4.85%, but challenges in asset utilization and debt management.

Portfolio Pulse from Benzinga Insights

September 13, 2024 | 4:00 pm

PINS

Piper Sandler analyst Thomas Champion has reiterated an Overweight rating on Pinterest (NYSE:PINS) and maintained a price target of $45.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 4:00 pm

EOLS

Barclays analyst Balaji Prasad maintains an Overweight rating on Evolus (NASDAQ:EOLS) and raises the price target from $16 to $20.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 3:59 pm

CNO

Piper Sandler analyst John Barnidge has reiterated an Overweight rating on CNO Financial Group (NYSE:CNO) and maintained a price target of $37.

Portfolio Pulse from Benzinga Newsdesk

September 13, 2024 | 3:56 pm

GRMN

MRNA

ORCL

Top Wall Street analysts have updated their price targets and ratings for several companies, including Oracle, Moderna, and Garmin. Notably, Guggenheim raised Oracle's price target, while Barclays significantly cut Garmin's target.

Portfolio Pulse from Avi Kapoor

September 13, 2024 | 3:54 pm